

# JW 55

**Catalog No: tcsc1757**



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

664993-53-7

**Formula:**

$C_{25}H_{26}N_2O_5$

**Pathway:**

Epigenetics;Cell Cycle/DNA Damage

**Target:**

PARP;PARP

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 50$  mg/mL (115.08 mM)

**Observed Molecular Weight:**

434.48


## Product Description

JW 55 is a potent and selective  **$\beta$ -catenin** signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with **IC<sub>50</sub>**s of 1.9  $\mu$ M and 830 nM respectively.

IC50 & Target: IC50: 1.9  $\mu$ M (TNKS1), 830 nM (TNKS2)<sup>[1]</sup>

**In Vitro:** JW 55 (JW55) is a potent and selective inhibitor of the canonical Wnt pathway. Wnt3a-induced HEK293 cells containing a transiently transfected ST-Luc (SuperTop-luciferase) reporter show inhibition by JW55 with an IC<sub>50</sub> value of 470 nM. JW55 is effective in the range of 1 to 5  $\mu$ M in SW480 cells and 0.01 to 5  $\mu$ M in HCT-15 cells. JW55 is effective in the range of 1 to 5  $\mu$ M in SW480 cells and 0.01 to 5  $\mu$ M in HCT-15 cells<sup>[1]</sup>.

**In Vivo:** JW 55 (100 mg/kg, orally) reduces tumor development in conditional *Apc* knockout mice. JW55 reduces XWnt8-induced axis duplication in *Xenopus* embryos and Tamoxifen-induced polyposis formation in conditional APC mutant mice<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!